|
April 12, 2006: Embolic Protection and Thrombectomy: If Yes, When, Who and How |
This video is sponsored by the Duke Clinical Medical Series.
Topics include: * Case Presentation * Embolic Protection and Thrombectomy If Yes: When, Who, and How? * Outline * Microembolization During Interventions (ACS) * SAFER Angiographic Predictors % Graft Diseased, Plaque Volume, Rx * Outline * Embolic Protection Devices * SAFER Primary Endpoint 30-day MACE (N = 801) * EMERALD: Infarct Size By Tc-99m SPECT (Infarct Size; % LV) * TriActiv System Key Components
The moderator, Peter Berger, MD, has indicated that he receives research/grant support from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also serves as Medical Director and has equity with Lumen, Inc.
The guest faculty, James Hermiller, MD, has indicated that he receives research/grant support from Cordis/Johnson & Johnson, Medtronic, BSC, and Guidant. He is a consultant for BSC, Guidant, and Anhoff.
n/a
|
| |